Patent Armory, Inc. v. Carbon Health Inc.: Voluntary Dismissal in Telecom Patent Case

Case Overview

The Parties

Patents at Issue

This case involved five U.S. patents asserted against Carbon Health, spanning core areas of communication routing and telephony management:

• • US9456086B1 — Intelligent communication routing system and method
• • US10491748B1 — Method and system for matching entities in an auction
• • US7269253B1 — Telephony control system with intelligent call routing
• • US7023979B1 — Telephony control system with intelligent call routing
• • US10237420B1 — Intelligent communication routing system and method

Litigation Timeline & Procedural History

In a litigation cycle completed in just 121 days, **Patent Armory, Inc. v. Carbon Health Inc.** (Case No. 1:24-cv-01312, D. Del.) concluded with a voluntary dismissal — before the defendant ever filed an answer. Filed on December 4, 2024, and closed on April 4, 2025, the case centered on five U.S. patents covering intelligent communication routing, telephony control, and auction-based entity matching systems — technologies directly relevant to modern digital health platforms.

The plaintiff, Patent Armory, Inc., invoked **Federal Rule of Civil Procedure 41(a)(1)(A)(i)** to voluntarily dismiss the action without prejudice, preserving its right to refile. For patent attorneys tracking NPE (non-practicing entity) assertion strategies, and for in-house counsel monitoring telecom patent infringement risk in health-tech, this case offers a compact but instructive snapshot of early-stage patent litigation dynamics in the District of Delaware.

The Verdict & Legal Analysis

Outcome

The case was **voluntarily dismissed without prejudice** by Patent Armory pursuant to **FRCP 41(a)(1)(A)(i)**. No damages were awarded. No injunctive relief was granted or denied. No claim construction, summary judgment, or trial proceedings occurred. The dismissal was self-executing — requiring no judicial order — and leaves Patent Armory free to refile the same claims against Carbon Health in the future, subject to applicable statutes of limitations and any future procedural considerations.

Verdict Cause Analysis

The procedural record does not disclose whether the parties engaged in any settlement negotiations, licensing discussions, or pre-answer motion practice. However, the structural circumstances warrant analysis:

Early voluntary dismissal by a PAE — particularly before the defendant answers — frequently signals one of several scenarios:

1. Pre-litigation licensing resolution: The parties may have reached a licensing agreement or settlement payment that rendered continued litigation unnecessary. This is a common resolution pattern for PAE-initiated telecom patent cases where defendants calculate settlement cost against litigation cost.
2. Claim re-evaluation: Plaintiff counsel may have identified claim construction vulnerabilities, prior art concerns, or product mapping issues after filing that warranted a strategic retreat and re-filing with a refined theory.
3. Jurisdictional or venue recalibration: Though Delaware is plaintiff-friendly, a change in strategic posture — such as targeting a different defendant, pursuing PTAB proceedings, or broadening assertions — could prompt early dismissal.

No court opinion, claim construction order, or validity ruling issued. Accordingly, **no precedential value attaches** to this specific proceeding on the merits of the asserted patents.

Legal Significance

Despite the absence of a merits ruling, the case carries instructive value:

• The five asserted patents span **two distinct technology clusters**: intelligent call routing/telephony (US7023979B1, US7269253B1, US9456086B1, US10237420B1) and auction-based entity matching (US10491748B1). Asserting both clusters simultaneously against a digital health company signals a broad mapping of telecom patent portfolios onto health-tech infrastructure.
• The **without-prejudice dismissal** means these five patents remain active litigation tools. Companies in adjacent spaces — telehealth, digital health platforms, patient communication systems — should treat these patent numbers as live assertion risks.
• Patent numbers **US7023979B1** and **US7269253B1**, both issuing from early-2000s applications, may face **Alice/§101 subject matter eligibility challenges** if re-litigated, given evolving post-*Alice Corp. v. CLS Bank* jurisprudence on abstract idea claims in communication routing contexts.

Strategic Takeaways

For Patent Holders and Assertion Entities:
Rule 41(a)(1)(A)(i) preserves maximum flexibility. Filing, then voluntarily dismissing before answer, can serve as a discovery mechanism — gauging defendant response posture, confirming product functionality, or securing a licensing conversation — without consuming full litigation resources.

For Accused Infringers:
When named in a PAE telecom patent complaint, early engagement with plaintiff counsel — even before filing a formal answer — may accelerate resolution. Companies should simultaneously commission **Freedom to Operate (FTO) analyses** against all asserted patent numbers and evaluate **IPR petition viability** at the USPTO for any patents with prior art exposure.

For R&D Teams:
Health-tech platforms with integrated call routing, intelligent scheduling, or patient communication systems face real infringement exposure from legacy telecom patent portfolios. Design-around documentation and early claim mapping during product development substantially reduces future litigation risk.